uniQure N.V.

NasdaqGS:QURE 株式レポート

時価総額:US$281.7m

uniQure 過去の業績

過去 基準チェック /06

uniQureの収益は年間平均-22.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19.3% 2.5%割合で 減少しています。

主要情報

-22.4%

収益成長率

-19.6%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率-2.5%
株主資本利益率-429.1%
ネット・マージン-837.8%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring

Oct 21

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 06

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 09

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

uniQure: The Valuation Got More Attractive

Feb 01

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

Jan 17
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Dec 15
A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Aug 27
Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Aug 06
Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Aug 02
Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Jul 02
uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

Jun 28
Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Apr 11
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Mar 01
News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Dec 09
Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug 08

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications

Apr 08

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure: Betting On Hemophilia-B Cure

Jan 18

収支内訳

uniQure の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:QURE 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 2429-24059-7
30 Jun 2428-285650
31 Mar 2419-297710
31 Dec 2316-308750
30 Sep 23112-2287515
30 Jun 23112-187710
31 Mar 23110-157620
31 Dec 22106-127550
30 Sep 2261-125510
30 Jun 2262-114490
31 Mar 22525324550
31 Dec 21524330560
30 Sep 21500321540
30 Jun 21500303520
31 Mar 2138-139460
31 Dec 2038-125430
30 Sep 206-166400
30 Jun 205-136380
31 Mar 206-124350
31 Dec 197-124340
30 Sep 196-105320
30 Jun 198-103290
31 Mar 199-92270
31 Dec 1811-83250
30 Sep 1812-90260
30 Jun 1811-78250
31 Mar 1813-78250
31 Dec 1713-79250
30 Sep 1720-67240
30 Jun 1725-72230
31 Mar 1724-71260
31 Dec 1625-73250
30 Sep 1620-76280
30 Jun 1616-90290
31 Mar 1614-90260
31 Dec 1511-82230
30 Sep 158-76180
30 Jun 156-58160
31 Mar 155-45140
31 Dec 146-50170
30 Sep 145-41150
30 Jun 146-42170
31 Mar 146-41170
31 Dec 134-37160

質の高い収益: QUREは現在利益が出ていません。

利益率の向上: QUREは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: QUREは利益が出ておらず、過去 5 年間で損失は年間22.4%の割合で増加しています。

成長の加速: QUREの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: QUREは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: QUREは現在利益が出ていないため、自己資本利益率 ( -429.05% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘